Strides receives USFDA approval for   Triamcinolone Acetonide Cream 

0 32,199

BizNextIndia: Pharma major Strides Pharma Science Limited (Strides) today announced that  its step‐down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has  received approval for Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5%. from the  United  States  Food  &  Drug  Administration  (US  FDA).  The product is a generic version of  Triamcinolone Acetonide Cream of Mylan Pharmaceuticals Inc.

According to IQVIA  MAT  data,  the  US market for Triamcinolone  Acetonide  Cream  USP,  0.025%, 0.1% and 0.5%. is approximately US$ 55 Mn. The product will be manufactured at flagship facility in Bangalore and will be marketed by Strides Pharma Inc. in the US market.   The company has  86  cumulative  ANDA filings with USFDA of which 56  ANDAs have been approved including 12 approvals received in FY 19.

Leave A Reply

Your email address will not be published.